Acinetobacter baumannii is a leading cause of complicated infections in the hospital environment, particularly among severely ill patients [1] . The crude mortality attributed to Acinetobacter species causing bloodstream infections is higher than 50 % [2] . Carbapenems have been one of the main antimicrobial classes used against A. baumannii infections [3] , but the emergence and dissemination of carbapenemases have diminished the utility of this class of drugs from an already limited list of existing treatment options [4] . In Brazil, it is known that carbapenem-resistant A. baumannii is considered endemic [5] , and the main lineages circulating in that country are those belonging to the clonal complexes (CCs) CC1, CC15 and CC79 [6, 7] . Among the alternatives for the treatment of infections due to carbapenem-resistant A. baumannii, polymyxins and other non-blactam agents, such as tetracyclines, may be valuable options [3] . Given the increasing rates of multidrug-(MDR) and extensively drug-resistant (XDR) A. baumannii [8], determination of the antimicrobial susceptibility of alternative agents is needed to assess the availability of potential therapeutic options. Thus, the aim of this study was to assess the in vitro activity of antimicrobial agents against carbapenemresistant A. baumannii isolates recovered from clinical specimens of patients from several hospitals in the state of São Paulo, Brazil.
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All isolates were confirmed to belong to A. baumannii species by internal transcribed spacer sequencing. ApaI-PFGE revealed the occurrence of 64 different restriction profiles (Simpson's index diversity, 0.997) grouped in seven PFGE clusters (named A to G in Fig. 1 ) and belonging mainly to (Institute Pasteur) CC1, CC15 and CC79. All the isolates presented the bla OXA-51 -like gene; the bla OXA-23 gene was detected in 68 (95.8 %) isolates, while bla OXA-72 and bla OXA-231 genes were detected in two (2.8 %) and one (1.4 %), respectively; combination of bla OXA-23 , bla OXA-72 and bla OXA-231 genes was not observed. Comprehensive data on population structure of such isolates were previously published [16] . Disc diffusion antimicrobial susceptibility revealed the occurrence of high resistance rates to aminoglycosides, fluoroquinolones, antipseudomonal penicillins+b-lactamase inhibitors, extendedspectrum cephalosporins and trimethoprim-sulfamethoxazole (Table 1 ). Imipenem and meropenem resistances were confirmed for all the isolates, while minocycline was the most active evaluated drug (100 % susceptibility). According to the US Food and Drug Administration breakpoints, 63.4 % of the isolates were non-susceptible to tigecycline (MIC >2 µg ml
À1
). We did not observe reduction in tigecycline MIC in the presence of 15 and 75 µg ml À1 of carbonyl cyanide-m-chlorophenylhydrazone and phenylalanine-arginine b-naphthylamide in relation to non-supplemented Mueller-Hinton agar, likely running out the impact of efflux pumps in the tigecycline resistance phenotype in a subset of six strains presenting the highest MIC values (6-12 µg ml
). The polymyxin B and colistin showed in vitro activity against 70 isolates (98.6 % of susceptibility); the remaining one (from urine source, isolated in 2012 and belonging to CC15) presented consistent polymyxin resistance for both drugs, with MIC of 128 µg ml À1 for polymyxin and 256 µg ml À1 for colistin. The MIC 50 and MIC 90 values for both polymyxin B and colistin remained low, though. We did not observe difference in the susceptibility patterns among the main CCs (CC1, CC15 and CC79) identified in this study or in specimen source or timing of the specimens (Table 2 ; Supplementary material). Sixty-one isolates (85.9 %) were classified as XDR, whereas the remaining 10 (14.1 %) were MDR (Fig. 1) .
Antimicrobial resistance is considered one of the most challenging issues from contemporary years [17] . Therefore, the identification of antimicrobial agents with activity against these multidrug resistance bacteria is encouraging. We verified high levels of XDR isolates among a diversified collection of carbapenem-resistant A. baumannii isolated from several health institutions across the state of São Paulo. However, susceptibility to three antimicrobial drugs with real potential for treatment of A. baumannii infections, minocycline, polymyxin B and colistin, was identified.
Minocycline is a tetracycline reintroduced in the US market in the late 2000s and is well recognized for its high levels of activity against several Gram-negative species [18] and its favourable pharmacokinetic properties [19] . These favourable features ensure minocycline as a promising option for treatment of infections due to MDR A. baumannii.
The polymyxins, however, have been a matter of concern since the 1970s. In the beginning, strong side effects (mainly nephrotoxicity and neurotoxicity) were attributed to polymyxins B and E (colistin), and their use was limited and classified as XDR, whereas the remaining 11 (14.1 %) were MDR. Oxacillinases genes (OXA genes) detected by PCR, isolate identification (key), year of isolation (year) and the seven clusters (A to G) are indicated. AK, Amikacin; CN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; TZP, piperacillin-tazobactam; TIM, ticarcillin-clavulanate; CTX, cefotaxime; FEP, cefepime; CAZ, ceftazidime; SXT, trimethoprim-sulfamethoxazole; SAM, ampicillin-sulbactam; IMP, imipenem; MEM, meropenem; TE, tetracycline; TGC, tigecycline; PB, polymyxin B; COL, colistin; MH, minocycline. discouraged. After the emergence and establishment of ESBL-and carbapenemase-producing Gram-negative bacteria, polymyxins were revisited and, until now, have displayed good activity against resistant Gram-negative bacteria [20] . The side effects were seen to be less aggressive than previously reported [21] .
Unexpectedly, 63.4 % of the studied A. baumannii isolates were non-susceptible to tigecycline (MIC >2 µg ml
), from which 8.5 % displayed resistance (MIC !8.0 µg ml À1 ). Recently, Cardoso et al. [22] reported similar results in a small set of 31 isolates from 14 hospitals in Brazil. Our more comprehensive data, including 71 isolates from 64 different institutions, reinforce their findings. In fact, a recently published meta-analysis did not recommend the use of a tigecycline-based regimen for the treatment of MDR A. baumannii infections [23] . Nonetheless, we are aware that our study presents potential limitations since the clear majority of our isolates presented the bla OXA-23 gene, from a particular geographic region.
Taken together, our findings highlight the potential use of minocycline and polymyxins for the treatment of infections due to MDR or XDR A. baumannii. Given the need of preserving the efficacy of last-line antimicrobial agents, continuous surveillance and rational prescribing are necessary for reducing the emergence and dissemination of new resistant determinants in clinical isolates of this life-threatening pathogen. ‡Including five isolates from catheter tips.
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